Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- BrightPath/Cellistic Pair Up for PI Trial of iPSC-derived NKT Cell
December 16, 2024
- RaQualia’s Acid Reducer Now Available in 5 Latin American Countries
December 13, 2024
- Daiichi Kicks Off PIII Quizartinib Study for FLT3-ITD Negative AML
December 12, 2024
- Kyowa Kirin to Globalize Research Organization after Orchard Buy
December 12, 2024
- Santen’s Glaucoma Drug Accepted for Review in Korea, Vietnam
December 12, 2024
- Eisai’s Gout Drug Urece Wins Nod in China
December 12, 2024
- ViiV to Hone In on Long-Acting Treatments for HIV: Japan President
December 11, 2024
- Ono Set for Japan Filing of SK Bio’s Epilepsy Med in FY2025
December 11, 2024
- It’s High Time to Rethink Market Price-Based Revision Scheme: Chugai CEO
December 10, 2024
- Daiichi Sankyo’s TROP2 ADC Gets Breakthrough Therapy Tag in US
December 10, 2024
- Off-Year Re-Pricing Will Ruin Investment Momentum: BMS Japan Chief
December 10, 2024
- Generic Industry Shakeup Advances as Teva Takeda Joins JWP-Medipal Group
December 9, 2024
- Santen Eye Care to Roll Out Alesion AGs on Jan. 20
December 9, 2024
- Japan Ethical Drug Sales Up 6.3% in October: Crecon
December 9, 2024
- LEO Pharma Japan Set to Follow Global Growth as Stand-Alone Sales Force Matures
December 9, 2024
- First Generics of Equa Priced at 30% of Original Product
December 6, 2024
- Mitsubishi, Dewpoint Join Hands on ALS Drug Targeting TDP-43
December 6, 2024
- Nxera Starts PIII Insomnia Drug Trial in South Korea; Data Due Out in 1H 2026
December 6, 2024
- Alzheimer’s Med Leqembi Approved in Mexico
December 6, 2024
- Keytruda Tops Drug Sales Ranking for 14th Month in November: Encise
December 6, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…